Annika Bansal – Lifestyle
Author:
ALTERITY THERAPEUTICS LIMITED
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
April 27, 2026
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
April 17, 2026
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
April 16, 2026
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
April 15, 2026
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
March 30, 2026
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
March 9, 2026
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
March 5, 2026
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
March 5, 2026